Free Trial

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 1.7% - Should You Sell?

Eupraxia Pharmaceuticals logo with Medical background
Remove Ads

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price traded down 1.7% during trading on Monday . The stock traded as low as $4.18 and last traded at $4.08. 3,152 shares changed hands during trading, a decline of 81% from the average session volume of 16,604 shares. The stock had previously closed at $4.15.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They set a "buy" rating and a $12.00 target price on the stock.

Get Our Latest Stock Report on EPRX

Eupraxia Pharmaceuticals Price Performance

The company has a market cap of $142.41 million and a P/E ratio of -5.55. The company has a fifty day simple moving average of $3.44 and a 200-day simple moving average of $3.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EPRX. Millennium Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $31,000. Raymond James Financial Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Bank of Montreal Can increased its holdings in shares of Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after buying an additional 7,500 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

Featured Stories

Should You Invest $1,000 in Eupraxia Pharmaceuticals Right Now?

Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.

While Eupraxia Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads